Clinical Trial Update: Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing regorafenib-pembrolizumab versus TACE/TARE in intermediate-stage hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Stivarga (regorafenib)

Snippet

Sponsor: Translational Research in Oncology | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: TERMINATED